Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

 
Phase: 1
Protocol No.Title
2015LS057RMT2015-46R: A Phase I Trial Testing NAM Expanded Haploidentical or Mismatched Related Donor Natural Killer (NK) Cells Followed by a Short Course of IL-2 for the Treatment of Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma
2015LS167HM2015-39 :GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE(TM)) for the Treatment of High Risk Myelodysplastic Syndromes,Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis
2016IS065An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts
2016IS192A Phase I/II, Open-Label, Multicenter, Dose Escalation Study of mRNA-2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection alone and in Combination with Durvalumab for Patients with Advanced Malignancies
2016IS194A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer
2016LS137Safety of Transarterial Chemoembolization in Patients with Elevated Bilirubin
2017CG087A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors (E7080-A001-216/ADVL1711)
2017IS090SGN22E-002: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
2017LS075Phase 1 Trial of Indole-3-Carbinol and Silibinin
2018CG056A Non-Randomized, Open-Label, Multi-center, Phase I/II Study of PI3K inhibitor Copanlisib in Pediatric Patients with Relapsed/Refractory Solid Tumors or Lymphoma (BAY 80-6946 /19176/ADVL1721)
2018IS003A PHASE 1/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-262 IN COMBINATION WITH NKTR-214 AND IN COMBINATION WITH NKTR-214 PLUS NIVOLUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
2018IS116MT2018-25 :Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)
2018IS166HM2018-34 A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin s Lymphoma
2018UC048A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination with Radiotherapy in Pediatric Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma (PNOC013)
2019CG013COG AINV18P1: A Phase 1 Study of Palbociclib (IND#141416), a CDK 4/6 Inhibitor, in Combination with Chemotherapy in Children with Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
2019CG040Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (IBRANCE®) in Combination With Irinotecan and Temozolomide and in Combination with Topotecan and Cyclophosphamide in Pediatric Patients With Recurrent or Refractory Solid Tumors Protocol No.: ADVL1921/A5481092
2019IS155HM2019-33:A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability, Efficacy,Pharmacokinetics, and Immunogenicity of TAK-573 (formerly TEV-48573) Administered Intravenously as a Single Agent in Patients With Refractory Multiple Myeloma
2019IS158MT2019-40: Ph I trial of FT596 in R/R B-cell Lymphoma and CLL
2019LS230MT2019-46: FATE FT596 with Rituximab as Relapse Prevention in High Risk Patients after Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma
2020IS043MT2020-06: A PHASE 1 STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TANDEMLY-PURIFIED ALLOGENEIC CD34+CD90+ HSC ADMINISTERED FOLLOWING CONDITIONING WITH AMG 191 TO ACHIEVE ENGRAFTMENT AND IMMUNE RECONSTITUTION IN PATIENTS WITH SCID
2020IS061MT2020-13 A Phase I, Open-Label, Multicenter Study of FT516 in Combination with Monoclonal Antibodies in Subjects with Advanced Solid Tumors
MT2009-09MT2009-09 Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Stem Cell Transplantation
PSYCH-2019-27460How Does the Brain Discriminate Between Internally- and Externally- Generated Stimuli?
PSYCH-2019-27473Precision Mental Health for Pregnant Women and Mothers: Addressing Unmet Cognitive Needs
PSYCH-2019-27663Brain Imaging-Based Care in Psychiatry (BIBCaP)